GO
Loading...

Novartis AG

More

  • Oct 16- The benefits of Novartis AG's anti-inflammation drug outweighed the risks in using it to treat a type of psoriasis, staff reviewers at the U.S. Food and Drug Administration said. There were no major safety issues associated with secukinumab, according to the review posted on the FDA website on Thursday- four days before a panel of outside advisers is...

  • Oct 16- The benefits of Novartis AG's anti-inflammation drug outweighed the risks in using it to treat a type of psoriasis, staff reviewers at the U.S. Food and Drug Administration said. While the FDA is not obligated to accept the recommendations of the panel, it typically does so. The FDA staff based its recommendation on the review of the data from this study,...

  • WASHINGTON, Oct 15- The U.S. Supreme Court on Wednesday appeared closely divided as it weighed Teva Pharmaceutical Industries Ltd's high-profile fight with generic drug manufacturers over patent protections for Copaxone, its top-selling multiple sclerosis drug. Israel- based Teva is battling to protect a key patent for the $4- billion- a-year MS drug that is...

  • WASHINGTON, Oct 15- The U.S. Supreme Court on Wednesday appeared closely divided as it weighed Teva Pharmaceutical Industries Ltd's high-profile fight with generic drug manufacturers over patent protections for Copaxone, its top-selling multiple sclerosis drug. The $4- billion- a-year drug accounts for 50 percent of Teva profits, and the patent fight is one...

  • WASHINGTON, Oct 15- The U.S. Supreme Court on Wednesday is set to wade into Teva Pharmaceutical Industries Ltd's fight over patent protections for Copaxone, its top-selling multiple sclerosis drug, in one of the most important business cases of the justices' new term. There are two teams developing cheaper generic forms of Copaxone: one involving Novartis AG's...

  • Oct 8- Amgen Inc said its copycat version of AbbVie Inc's blockbuster biotech drug Humira showed comparable safety and ability to generate immune response in patients with a type of skin disease. "We remain bullish about AMGN's biosimilar prospects given the manufacturing expertise which would likely be key for success in biosimilar competition," Deutsche...

  • GSK investigating corruption allegations in UAE Wednesday, 8 Oct 2014 | 1:17 AM ET

    GlaxoSmithKline, which was slapped with a record fine for corruption in China, said it was looking into allegations of corruption in UAE.

  • *GSK says UAE investigations part of wider Middle East probe. LONDON, Oct 7- Drugmaker GlaxoSmithKline, which was slapped with a record $489 million fine for corruption in China last month, said on Tuesday it was looking into allegations of corruption in the United Arab Emirates. The company is already investigating alleged bribery in a number of Middle East...

  • Oct 3- The U.S. Supreme Court's new term is due to begin on Monday. *Texas Department of Housing and Community Affairs v. In July 2013, the appeals court ruled in favor of two teams developing cheaper generic forms of Copaxone: one involving Novartis AG's Sandoz Inc and Momenta Pharmaceuticals Inc and another involving Mylan Inc and Natco Pharma Ltd..

  • *No EU concerns about Eli Lilly, Novartis deal. In contrast, U.S. drugmaker Eli Lilly's proposed $5.4 billion takeover of Swiss peer Novartis's animal health business triggered no such worries and will be cleared unconditionally, the sources said. Eli Lilly is buying the Novartis unit to strengthen and diversify its Elanco unit.

  • Oct 2- Ariad Pharmaceuticals Inc said its experimental lung cancer drug was granted "breakthrough therapy" status by the U.S. Food and Drug Administration, sending the company's shares up as much as 13 percent. Ariad said the designation was based on early results that showed the drug continued to fight against lung cancer in patients who did not respond to...

  • NEW YORK, Oct. 1- Two tiny companies are preparing to challenge some of the world's largest drug makers in the battle for dominance in the $3 billion global market for influenza vaccines, armed with little more than tiny tobacco plants.

  • NEW YORK, Sept 30- A federal judge said Novartis AG must face a U.S. government lawsuit accusing the Swiss drugmaker of paying multimillion-dollar kickbacks, including a $9,750 dinner for three at a Japanese restaurant, to induce doctors to prescribe its drugs.

  • *Roche set to compete with established GSK combination. *Shares in Roche's biotech partner Exelixis jump 20 pct. MADRID, Sept 29- Rival two-pill combinations for melanoma from Roche and GlaxoSmithKline had similarly good results in separate clinical trials, leaving doctors with little to choose between the two skin cancer courses.

  • FRANKFURT, Sept 22- Drugs and chemicals maker Merck KGaA agreed on Monday to acquire U.S.-based Sigma-Aldrich Corp for $17 billion in cash to boost its lab supplies business, the biggest takeover in the German group's history.

  • FRANKFURT, Sept 22- Drugs and chemicals maker Merck KGaA agreed on Monday to acquire U.S. company Sigma-Aldrich for $17 billion in cash to boost its lab supplies business, the biggest takeover in the German group's history.

  • LONDON, Sept 22- GlaxoSmithKline may have closed one chapter in a saga of corruption allegations by accepting a $489 million fine in China, but the drugmaker has its work cut out to win back sceptical investors.

  • For Roche CEO, celebrating failure is key to success Wednesday, 17 Sep 2014 | 8:06 AM ET

    LONDON, Sept 17- Roche Chief Executive Severin Schwan likes to crack open the champagne with his drug research teams at the end of a big project- especially when they fail.

  • Switzerland takes on its top drugmakers in price row Tuesday, 16 Sep 2014 | 5:46 AM ET

    *Roche, Novartis say low prices hurt R&D. ZURICH, Sept 16- Switzerland, home to the world's two biggest drugmakers, might be expected to give them an easy ride. But Roche and Novartis are finding no immunity in their home market from a European-wide price squeeze.

  • *Roche, Novartis say Lucentis is most appropriate drug. Avastin is not licensed for wAMD but it works in a similar way to authorized treatments for the condition- Lucentis, which is marketed by Novartis and Roche, and Eylea, from Bayer and Regeneron Pharmaceuticals.